Genzyme Corporation today announced that the FDA's Orthopaedic and Rehabilitation Devices Advisory Committee voted unanimously (5 - 0) in favor of approval without conditions of Synvisc-One TM (hylan ...

CAMBRIDGE, Mass., Nov. 13 /PRNewswire-FirstCall/ -- Genzyme Corp. announced today that it has received a letter from the U.S. Food and Drug Administration requesting ...

(Recasts first paragraph; adds Genzyme comments, sales figures, competitors, byline; updates stock price) By Lisa Richwine GAITHERSBURG, Md., Dec 9 (Reuters) - A U.S. advisory panel has unanimously ...

Feb. 6, 2003 (New Orleans) — In a head-to-head study comparing intra-articular hylan GF-20 injection (Synvisc) to corticosteroid injection for knee osteoarthritis, "there was no difference in outcome ...

BOSTON, Feb 26 (Reuters) - Genzyme Corp said on Thursday it has won European approval to make its drug Myozyme at a 4,000-liter manufacturing facility, expanding supply for patients with the rare ...

To earn CME related to this news article, click here. March 5, 2009 — The US Food and Drug Administration (FDA) has approved budesonide plus formoterol fumarate dihydrate inhalation aerosol for the ...

A federal panel of advisers Tuesday voted unanimously in favor of approval of Genzyme Corp.'s Synvisc-One, an investigational injectable product intended to relieve pain associated with osteoarthritis ...

Please provide your email address to receive an email when new articles are posted on . Sanofi has issued a limited voluntary recall of its Synvisc-One, an injected gel for treating arthritis, due to ...

For Synvisc-One, you report 48 units of the J7325 code for the single visit, instead of reporting a regular Synvisc injection that occurs over a series of three visits. For the regular Synvisc ...